30th Jun 2026 07:00
30 June 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Change of Corporate Broker
Cizzle Biotechnology is pleased to announce the appointment of Zeus Capital Limited as the Company's sole Corporate Broker with immediate effect.
Enquiries:
Cizzle Biotechnology Holdings plc | Via IFC Advisory |
Allan Syms (Executive Chairman) |
Allenby Capital Limited (Financial Adviser) | +44(0) 20 3328 5656 |
John Depasquale (Corporate Finance) | |
Zeus (Corporate Broker) James Hornigold, Alex Slater (Investment Banking) Nick Searle (ECM) |
+44(0) 20 3829 5000 |
IFC Advisory Limited | +44(0) 20 3934 6632 |
Tim Metcalfe | |
Florence Staton |
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care. Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
Related Shares:
Cizzle Biotech